Changes in mRNA/protein expression and signaling pathways in in vivo passaged mouse ovarian cancer cells
暂无分享,去创建一个
K. Nephew | J. Wan | David F. B. Miller | Sheng Liu | Yan Xu | A. Buechlein | Qingchun Cai | Qipeng Fan
[1] M. Rinaldi,et al. GLUT 1 receptor expression and circulating levels of fasting glucose in high grade serous ovarian cancer , 2018, Journal of cellular physiology.
[2] U. Ray,et al. Aberrant lipid metabolism in cancer cells – the role of oncolipid‐activated signaling , 2018, The FEBS journal.
[3] Ho-Yyoung Lee,et al. Oncogene-Driven Metabolic Alterations in Cancer , 2017, Biomolecules & therapeutics.
[4] A. Jemal,et al. Cancer statistics, 2018 , 2018, CA: a cancer journal for clinicians.
[5] Haiyan Zhang,et al. High ALDH activity defines ovarian cancer stem-like cells with enhanced invasiveness and EMT progress which are responsible for tumor invasion. , 2018, Biochemical and biophysical research communications.
[6] A. Jemal,et al. Factors That Contributed to Black-White Disparities in Survival Among Nonelderly Women With Breast Cancer Between 2004 and 2013. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] M. Knight,et al. Deconstruction of a Metastatic Tumor Microenvironment Reveals a Common Matrix Response in Human Cancers. , 2018, Cancer discovery.
[8] M. Matzuk,et al. CRISPR/Cas9-derived models of ovarian high grade serous carcinoma targeting Brca1, Pten and Nf1, and correlation with platinum sensitivity , 2017, Scientific Reports.
[9] W. Woodward,et al. Effect of statins on breast cancer recurrence and mortality: a review , 2017, Breast cancer.
[10] K. Odunsi. Immunotherapy in ovarian cancer. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[11] C. Denkert,et al. High-grade ovarian serous carcinoma patients exhibit profound alterations in lipid metabolism , 2017, Oncotarget.
[12] I. Shih,et al. The novel ZIP4 regulation and its role in ovarian cancer , 2017, Oncotarget.
[13] Changxiu Wang,et al. Clinical significance and biological role of Wnt10a in ovarian cancer , 2017, Oncology letters.
[14] K. O'Byrne,et al. Targeting the cancer stem cell marker, aldehyde dehydrogenase 1, to circumvent cisplatin resistance in NSCLC , 2017, Oncotarget.
[15] M. Stack,et al. Complex Determinants of Epithelial: Mesenchymal Phenotypic Plasticity in Ovarian Cancer , 2017, Cancers.
[16] G. Rice,et al. The Crosstalk between Ovarian Cancer Stem Cell Niche and the Tumor Microenvironment , 2017, Stem cells international.
[17] M. Ruchała,et al. Genomic markers of ovarian adenocarcinoma and its relevancy to the effectiveness of chemotherapy , 2017, Oncology letters.
[18] Yan Xu,et al. lpa regulates sox9 in ovarian cancer cells , 2017 .
[19] J. Lang,et al. Statin use and survival outcomes in endocrine-related gynecologic cancers: A systematic review and meta-analysis , 2017, Oncotarget.
[20] U. Cavallaro,et al. Ovarian cancer stem cells: still an elusive entity? , 2017, Molecular Cancer.
[21] K. Busam,et al. The NF1 gene in tumor syndromes and melanoma , 2017, Laboratory Investigation.
[22] I. Vergote,et al. Ovarian cancer and the immune system , 2017, Gynecologic oncology reports.
[23] A. Jemal,et al. Cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.
[24] I. McNeish,et al. CRISPR/Cas9-Mediated Trp53 and Brca2 Knockout to Generate Improved Murine Models of Ovarian High-Grade Serous Carcinoma. , 2016, Cancer research.
[25] H. Donninger,et al. Ras signaling through RASSF proteins. , 2016, Seminars in cell & developmental biology.
[26] Yuquan Wei,et al. Tumor microenvironment: The culprit for ovarian cancer metastasis? , 2016, Cancer letters.
[27] K. Hayashi,et al. WNT7A Regulation by miR-15b in Ovarian Cancer , 2016, PloS one.
[28] J. Ajduković. HIF-1--a big chapter in the cancer tale. , 2016, Experimental oncology.
[29] Zhenwen Zhao,et al. The Lipidomic Analyses in Low and Highly Aggressive Ovarian Cancer Cell Lines , 2016, Lipids.
[30] H. Katabuchi,et al. CD44 variant 6 is correlated with peritoneal dissemination and poor prognosis in patients with advanced epithelial ovarian cancer , 2015, Cancer science.
[31] Zhuling Yang,et al. Musashi-1 Expression is a Prognostic Factor in Ovarian Adenocarcinoma and Correlates with ALDH-1 Expression , 2015, Pathology & Oncology Research.
[32] Yan Xu,et al. The microenvironment reprograms circuits in tumor cells , 2015, Molecular & cellular oncology.
[33] Yan Xu,et al. Anoikis resistance is a critical feature of highly aggressive ovarian cancer cells , 2014, Oncogene.
[34] Jingru Zhang,et al. The expression of VEGF and Dll4/Notch pathway molecules in ovarian cancer. , 2014, Clinica chimica acta; international journal of clinical chemistry.
[35] C. Denkert,et al. Overexpression of the epithelial cell adhesion molecule is associated with a more favorable prognosis and response to platinum-based chemotherapy in ovarian cancer , 2014, Journal of gynecologic oncology.
[36] Zhihong Zhang,et al. Cancer stem cells, epithelial-mesenchymal transition, and drug resistance in high-grade ovarian serous carcinoma. , 2013, Human pathology.
[37] E. Levanon,et al. Human housekeeping genes, revisited. , 2013, Trends in genetics : TIG.
[38] Haixu Tang,et al. A new method for stranded whole transcriptome RNA-seq. , 2013, Methods.
[39] J. Pouysségur,et al. Disrupting proton dynamics and energy metabolism for cancer therapy , 2013, Nature Reviews Cancer.
[40] R. Berkowitz,et al. Characterization of aldehyde dehydrogenase isozymes in ovarian cancer tissues and sphere cultures , 2012, BMC Cancer.
[41] K. Green,et al. Desmoplakin regulates desmosome hyperadhesion , 2011, The Journal of investigative dermatology.
[42] Benjamin J. Raphael,et al. Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.
[43] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[44] G. Sandusky,et al. Group VIA phospholipase A2 in both host and tumor cells is involved in ovarian cancer development , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[45] M. A. Khan,et al. Association of lipid metabolism with ovarian cancer. , 2010, Current oncology.
[46] H. An,et al. Prognostic significance of Notch 3 gene expression in ovarian serous carcinoma , 2010, Cancer science.
[47] Tian-Li Wang,et al. Jagged1 Expression Regulated by Notch3 and Wnt/β-catenin Signaling Pathways in Ovarian Cancer , 2010, Oncotarget.
[48] Mark D. Robinson,et al. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..
[49] H. Frierson,et al. PRK1 distribution in normal tissues and carcinomas: overexpression and activation in ovarian serous carcinoma. , 2009, Human pathology.
[50] M. Fong,et al. Ovarian cancer mouse models: a summary of current models and their limitations , 2009, Journal of ovarian research.
[51] Hanna Y. Irie,et al. Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment , 2009, Nature.
[52] Dongmei Wang,et al. Lysophosphatidic acid stimulates cell migration, invasion, and colony formation as well as tumorigenesis/metastasis of mouse ovarian cancer in immunocompetent mice , 2009, Molecular Cancer Therapeutics.
[53] Robert A. Harris,et al. Pyruvate Dehydrogenase Complex Activity Controls Metabolic and Malignant Phenotype in Cancer Cells* , 2008, Journal of Biological Chemistry.
[54] Curt Balch,et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. , 2008, Cancer research.
[55] P. Shaw,et al. Epithelial-stromal interaction increases cell proliferation, survival and tumorigenicity in a mouse model of human epithelial ovarian cancer. , 2008, Gynecologic oncology.
[56] C. Carlberg,et al. Meta-analysis of primary target genes of peroxisome proliferator-activated receptors , 2007, Genome Biology.
[57] D. Stoffer,et al. PI3K is negatively regulated by PIK3IP1, a novel p110 interacting protein. , 2007, Biochemical and biophysical research communications.
[58] S. Mok,et al. Hypoxia enhances lysophosphatidic acid responsiveness in ovarian cancer cells and lysophosphatidic acid induces ovarian tumor metastasis in vivo. , 2006, Cancer research.
[59] D. Katafiasz,et al. Carboxyl Terminus of Plakophilin-1 Recruits It to Plasma Membrane, whereas Amino Terminus Recruits Desmoplakin and Promotes Desmosome Assembly* , 2006, Journal of Biological Chemistry.
[60] M. Clarke,et al. Stem Cells and Cancer: Two Faces of Eve , 2006, Cell.
[61] Hung,et al. Enhanced c-erbB2 / neu Expression in Human Ovarian Cancer Cells Correlates with More Severe Malignancy That Can Be Suppressed by EIA 1 , 2006 .
[62] A. Becker,et al. GLUT1 mRNA and Protein Expression in Ovarian Borderline Tumors and Cancer , 2004, Oncology.
[63] I. Weissman,et al. Stem cells, cancer, and cancer stem cells , 2001, Nature.
[64] J L Pace,et al. Development of a syngeneic mouse model for events related to ovarian cancer. , 2000, Carcinogenesis.
[65] C. Dinney,et al. Highly metastatic human prostate cancer growing within the prostate of athymic mice overexpresses vascular endothelial growth factor. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[66] Mike Wilson,et al. Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.
[67] M. Hung,et al. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A. , 1993, Cancer research.
[68] I. Fidler,et al. Selection of successive tumour lines for metastasis. , 1973, Nature: New biology.